DCGI sends notice to Glenmark for false claims, overpricing of COVID-19 drug FabiFlu
4 years, 5 months ago

DCGI sends notice to Glenmark for false claims, overpricing of COVID-19 drug FabiFlu

India TV News  

The Drug Controller General of India has sent a show cause notice to Glenmark Pharmaceuticals over 'overpricing' and alleged 'false claims' of its drug Fabiflu. The DCGI also said that Glenmark made claims that Fabiflu alone would suffice as treatment in mild and moderate coronavirus cases and that it is effective for patients with comorbidities. "It has been mentioned in representation that Glenmark has claimed that this drug is effective in co-morbid conditions like hypertension, diabetes whereas in reality, as per protocol summary, this trial was not designed to assess the Fabiflu in co-morbid conditions. The notice stated that the DCGI has received reports that Fabiflu -- a version of favipiravir -- has been priced at Rs 12,500 for the entire course.

False Claims Notice Drug Dcgi Glenmark Fabiflu  fabiflu  claims  rs  notice  glenmark  covid19  dcgi  day  tablets  drug  false  favipiravir  sends  overpricing  priced

History of this topic

Prices of 800 essential medicines, including Paracetamol, set to rise by 10.7% from April
2 years, 8 months ago

Prices of 800 essential medicines, including Paracetamol, set to rise by 10.7% from April

India Today  

The National Pharmaceutical Pricing Authority of India on Friday announced a 10.7 per cent change in the Wholesale Price Index for the calendar year 2021 over the corresponding period in 2020. This means that the prices of nearly 800 scheduled medicines on the National List of Essential Medicines, which are used to treat the majority of common ailments, will rise …

Paracetamol, Azithromycin, Ivermectin: Essential Medicines Might Face Shortage If API Costs Continue to Rise
3 years, 7 months ago

Paracetamol, Azithromycin, Ivermectin: Essential Medicines Might Face Shortage If API Costs Continue to Rise

News 18  

As continuous surge in number of Covid-19 cases is being reported from across the country, people have resorted to panic buying and started hoarding basic medicines required for the treatment. While most manufacturers are working towards building up inventory for these essential drugs that could last for three to six months, the fact remains that they are comprising with their …

BDR Pharma To Launch Favipiravir Tablets for Treating Covid-19 Patients at Rs 990
4 years, 3 months ago

BDR Pharma To Launch Favipiravir Tablets for Treating Covid-19 Patients at Rs 990

News 18  

New Delhi: Drug firmBDR Pharmaceuticals on Friday said it plans to launch400 mg Favipiravir tablets, used for treating COVID-19 patients, in the country. The ‘BDFAVI’ 400 mg tablets will be priced at Rs 990 for a strip of 10 tablets, BDR Pharma said in a statement. “We aim to make BDFAVI available in sufficient quantities to meet the high demand …

Brinton Pharma Gets DCGI Nod to Launch Favipiravir 400 mg Tablets for Covid-19 Treatment
4 years, 4 months ago

Brinton Pharma Gets DCGI Nod to Launch Favipiravir 400 mg Tablets for Covid-19 Treatment

News 18  

Brinton Pharmaceuticals on Thursday said it has received approval from the Drugs Controller General of India to launch Favipiravir 400 mg tablets under the brand name Faviton for Rs 79 per tablet. The tablets are indicated for the treatment of patients with mild to moderate COVID-19 symptoms, Brinton Pharmaceuticals said in a statement. The tablets will be available across all …

Glenmark to Launch 400 mg of Antiviral Drug FabiFlu for Covid-19 Treatment
4 years, 4 months ago

Glenmark to Launch 400 mg of Antiviral Drug FabiFlu for Covid-19 Treatment

News 18  

Drug firm Glenmark Pharmaceuticals on Thursday said it will launch a 400 mg version of oral antiviral drug FabiFlu for the treatment of mild and moderate COVID-19 in India. The higher strength will improve compliance for patients by effectively reducing the number of tablets required per day, Glenmark said in a statement. Glenmark is the first company in India to …

Zenara Pharma gets DCGI approval to sell Favipiravir tablet Favizen to treat mild to moderate COVID-19 infections
4 years, 4 months ago

Zenara Pharma gets DCGI approval to sell Favipiravir tablet Favizen to treat mild to moderate COVID-19 infections

Firstpost  

The company is in talks with various institutions to make the tablets available at discounted or no cost to underprivileged patients. Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, announced that it has received approval from the Drugs Controller General of India, to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate …

Zenara Pharma Receives DCGI Approval to Manufacture, Sell Favipiravir Tablets
4 years, 4 months ago

Zenara Pharma Receives DCGI Approval to Manufacture, Sell Favipiravir Tablets

News 18  

Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, announced that it has received approval from the Drugs Controller General of India, to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19. Jagadeesh Babu Rangisetty, Co-founder and Managing Director of the firm, said, "In the ongoing pandemic, it has become …

Lupin launches antiviral drug Favipiravir under the name Covihalt to treat mild to moderate COVID-19 infection
4 years, 4 months ago

Lupin launches antiviral drug Favipiravir under the name Covihalt to treat mild to moderate COVID-19 infection

Firstpost  

The Covihalt tablet will be available in 200 mg tablets in a strip of 10 and will cost Rs 49 per tablet in India. Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name ‘Covihalt’ for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India. Its Covihalt …

Sun Pharma Launches Antiviral Covid-19 Drug Favipiravir in India at Rs 35 Per Tablet
4 years, 4 months ago

Sun Pharma Launches Antiviral Covid-19 Drug Favipiravir in India at Rs 35 Per Tablet

News 18  

India’s Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world’s third worst-hit nation. Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge …

The many questions about Favipiravir
4 years, 6 months ago

The many questions about Favipiravir

The Hindu  

The pandemic has not only exposed the dire situation of the public health infrastructure, but also the opacity with which drug/medical device approvals are granted in India. After the outbreak of COVID-19, doctors in China and Russia started using it to treat COVID-19 patients although there is no scientific consensus on the efficacy of the drug. As per Glenmark’s filing …

Glenmark says FabiFlu reduces viral load by 4 days, treats mild to moderate COVID-19 patients
4 years, 6 months ago

Glenmark says FabiFlu reduces viral load by 4 days, treats mild to moderate COVID-19 patients

India TV News  

Glenmark has become the first pharmaceutical company in India to receive regulatory approval for oral antiviral favipiravir, for the treatment of mild to moderate COVID-19. The company has received manufacturing and marketing approval from India's drug regulator, making FabiFlu the first oral Favipiravir-approved medication in India for the treatment of COVID-19.​ Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced …

Glenmark Pharmaceuticals shares soar 20 per cent after COVID-19 drug Favipiravir launch
4 years, 6 months ago

Glenmark Pharmaceuticals shares soar 20 per cent after COVID-19 drug Favipiravir launch

India TV News  

Shares of Glenmark Pharmaceuticals on Monday rallied 20 per cent after the company said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19. The scrip jumped 19.99 per cent to Rs 490.90 -- its upper circuit limit -- on the BSE. On the NSE, it zoomed 19.99 per …

Hetero launches drug for COVID-19 patients
4 years, 6 months ago

Hetero launches drug for COVID-19 patients

The Hindu  

Drugmaker Hetero has received the Drug Controller-General of India approval to manufacture and sell its generic version of Gilead’s Remdesivir for the treatment of COVID-19 patients in the country. Besides Hetero, a clutch of other drugmakers, including Jubilant Lifesciences, Mylan, Dr. Reddy’s Laboratories, Biocon company Syngene and Zydus Cadila Healthcare, have entered into non-exclusive, voluntary licensing agreements with Gilead under …

Coronavirus | Drug launched for moderate COVID-19 cases
4 years, 6 months ago

Coronavirus | Drug launched for moderate COVID-19 cases

The Hindu  

Glenmark Pharmaceuticals Limited has announced the introduction of Favipiravir under the brand name FabiFlu in tablet form for the treatment of mild & moderate coronavirus cases in India. FabiFlu is India’s first oral antiviral drug for treatment of mild & moderate COVID-19 patients, the company said. The priority is to make the drug available to as many patients and save …

Coronavirus | Glenmark’s antiviral drug Fabiflu to be used for patients with mild and moderate symptoms
4 years, 6 months ago

Coronavirus | Glenmark’s antiviral drug Fabiflu to be used for patients with mild and moderate symptoms

The Hindu  

Glenmark Pharmaceuticals had on Friday received manufacturing and marketing approval from India’s drug regulator, making FabiFlu the first oral Favipiravir-approved medication in India for the treatment of COVID-19. FabiFlu will be used for treating COVID-19 patients with mild to moderate symptoms and will be made available from today evening and by next week across the country. Once administered the drug …

Glenmark launches COVID-19 drug after DCGI nod
4 years, 6 months ago

Glenmark launches COVID-19 drug after DCGI nod

India TV News  

Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19. FabiFlu has demonstrated an encouraging response in mild to moderate COVID-19 patients during clinical trials, Saldanha said. It had then filed the product for clinical trial with country's drug regulator DCGI and became the …

Indian regulators give Glenmark approval to manufacture, sell favipiravir for ‘restricted emergency use’ in treating COVID-19 patients
4 years, 6 months ago

Indian regulators give Glenmark approval to manufacture, sell favipiravir for ‘restricted emergency use’ in treating COVID-19 patients

Firstpost  

Glenmark Pharmaceuticals Ltd has received Indian regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 infections in the country Bengaluru: Glenmark Pharmaceuticals Ltd has received Indian regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 infections in the country, it said on Friday. The Mumbai-based company said the approval was …

Discover Related